BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
HealthUnited States Food and Drug AdministrationplinabulinImperial Chemical Industriesnon-small-cell lung carcinoma